Giancarlo Castaman
University of Florence
435 Papers
3.6K Citations
Giancarlo Castaman is an academic researcher from University of Florence. The author has contributed to research in topics: Medicine & Von Willebrand disease. The author has an hindex of 60, co-authored 389 publications. Previous affiliations of Giancarlo Castaman include UniFi & University of Milan.
Chat about Author
Papers
thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential
Tiziano Barbui,Tommaso Za,Luigi Gugliotta,Alessia Tieghi,Maria Gabriella Mazzucconi,Cristina Santoro,Guido Finazzi,Federica Delaini,Caterina Micò,Alessandro M. Vannucchi,Elisabetta Antonioli,Marco Ruggeri,Francesco Rodeghiero,Alberto Tosetto,Giancarlo Castaman,Francesca Scognamiglio +15 more
- 01 Jan 2013
TL;DR: Post-surgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey.
Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B
W. S. Pipe,WG F Leebeek,Michael Recht,S. N. Key,Susan U. Lattimore,Giancarlo Castaman,D. Cooper,S. Verweij,Robert Dolmetsch,John C. Tarrant,Y. Li,E. P. Monahan,WA Miesbach +12 more
TL;DR: In this article , the safety and efficacy of etranacogene dezaparvovec in HOPE-B participants with and without (NAb+) neutralizing antibodies (NAbs) were investigated.
Pain relief with Eptacog beta in haemophilia patients with inhibitors
Ulrike Nowak-Göttl,Cédric Hermans,Jenetha Mahlangu,Sanjay P. Ahuja,Manuel Carcao,Giancarlo Castaman,J. Davis,Osman Khan,Wolfgang Miesbach,M. Reding,J.-F. Schved,L. Villareal Martinez,M. Wang,Jerzy Windyga,Michelle Witkop,Guy Young,Daniel Bonzo,I Mitchell,Clarence Henry Kessler +18 more
TL;DR: In this article , the impact of eptacog beta treatment on pain relief across two different age groups using data from the pivotal clinical trials was described, where the authors used the EPTACog beta for the treatment of BEs in patients with congenital hemophilia A or B with inhibitors.
A contribution to the debate about the possible different clinical severity between hemophilia A and B
TL;DR: The authors' patient population consisted of patients consecutively enrolled according to regular check-up followup, and the temporal interval was the same for patients with hemophilia A and B since all the patients were routinely enrolled.
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study
MT Álvarez,Giancarlo Castaman,Maissaa Janbain,Ina Lunk,Martin Sanabria,Toru Matsushita,Karina Meijer,Johannes Oldenburg,M. Reding +8 more
TL;DR: The most recent interim analysis of the HEM-POWR study (NCT03932201) demonstrated the effectiveness and safety of damoctocog alfa pegol in previously treated patients (PTPs) with haemophilia A in a real-word setting as mentioned in this paper .